Doravirine maintains higher rate of virological suppression over darunavir/ritonavir though 96 weeks of follow-up
Reduced dose darunavir/ritonavir effective and safe for people switching while virally suppressed
Three-quarters of deaths of people with HIV in London are due to non-AIDS conditions
The kick that didn’t kill: first-ever randomised HIV cure study fails to eliminate infected cells
Why are some countries slow to implement HIV treatment guidelines?
Dolutegravir dual therapy works well for first-time HIV treatment
PrEP does not lower feminising hormone level in transgender women
Dolutegravir: update on infant neural tube defects from Botswana
Dolutegravir-based ART recommended for all – if reliable contraception is available
